CVS Can Block a Suspicious Prescriber. What Does This Mean for Patients on Opioids?

— Evaluation of outcomes can help establish if the restrictions have clinical benefit

Stopping harmful prescribing and reducing the patient's overall risk belong in the same intervention. Although blocking a suspicious prescriber can prevent further unsafe dispensing of controlled substances, its clinical benefit also depends on whether patients subsequently receive appropriate care. Pain, physical dependence, and opioid use disorder can persist after access to a prescription ends, including when these conditions arise from the prescribing that prompted intervention.

The $315 million CVS opioid settlementopens in a new tab or window announced on October 13 provides an opportunity to examine this transition. The agreement resolves federal allegations involving unlawful dispensing and false claims, without an admission of liability. Medically unnecessary opioids and dangerous combinations of controlled substances can expose patients to overdose and death. Preventing these exposures is an essential component of the response to unsafe prescribing.

The accompanying Drug Enforcement Administration (DEA) memorandumopens in a new tab or window requires CVS to block controlled-substance prescriptions from prescribers whose DEA registration or state license has been suspended or revoked. Separately, it requires CVS to block a prescriber across its retail pharmacies when prescribing concerns remain unresolved after review, unless prohibited by law. The memorandum requires reporting of blocked prescribers but does not expressly require assessment of their patients' subsequent health outcomes.

Comparable provisions appeared in CVS's 2022 multistate settlementopens in a new tab or window. The latest agreement therefore reinforces an established approach whose evaluation should include whether patients reach safer care.

The distinction between restricting dispensing and reducing overall risk is clinically consequential. Patients receiving prescriptions from the same clinician differ in their underlying conditions, treatment histories, and access to alternative care. Some might benefit from the immediate prevention of dangerous dispensing. Others might require reassessment, management of physical dependence, or treatment for opioid use disorder. These needs are not resolved by the restriction itself. Patients who have received inappropriate treatment still need a safe transition from it.

Evidence concerning opioid treatment disruption supports attention to this transition. FDA warnings identifyopens in a new tab or window severe withdrawal, uncontrolled pain, and suicide following rapid reduction or abrupt discontinuation of opioid analgesics in physically dependent patients. CDC guidance similarly cautions against rigid restrictions and patient abandonmentopens in a new tab or window. In a large observational studyopens in a new tab or window published in JAMA, tapering among patients receiving stable, long-term, higher-dose opioids was associated with increased rates of overdose and mental-health crises.

These findings do not establish that prescriber blocks cause similar outcomes. A pharmacy block differs from a dose taper, and patients might obtain appropriate treatment elsewhere. Nevertheless, the evidence identifies potential consequences of treatment interruption that warrant consideration when evaluating restrictions on controlled substance dispensing. The clinical need for a managed transition can be substantial even if the original treatment was unsafe.

Several outcomes are possible after a prescriber is blocked. Patients might receive safer treatment from another clinician, continue a dangerous regimen through another pharmacy, or experience a prolonged interruption in care. These trajectories have different implications for patient safety, yet all are possible after a prescriber is blocked from a pharmacy. Reduced dispensing alone cannot distinguish successful intervention from displacement of unsafe treatment or loss of needed care.

An independent evaluation of patient outcomes would help establish whether these restrictions achieve their intended clinical benefit. This is my proposed extension of the settlement's reporting requirements. It would require following patients across care settings because CVS dispensing records alone cannot establish whether patients subsequently receive safer treatment or experience adverse events elsewhere.

A focused, independent evaluation could begin with one insurer's population. Linking CVS prescriber-block dates with pharmacy and medical claims would allow researchers to identify patients who had been filling opioid prescriptions at CVS from those prescribers before the block and follow their subsequent care, including treatment received elsewhere. Treatment gaps, subsequent dispensing, and emergency visits could be assessed against carefully selected comparison patients and prior trends. Such an evaluation would provide an initial basis for examining both the benefits of restricting unsafe dispensing and the consequences of the subsequent transition.

Causal interpretation would require particular attention to the circumstances prompting intervention. Patients of blocked prescribers might already face increased risks because of unsafe regimens, underlying illness, or other characteristics associated with the prescribing concerns. Adverse events after a block could reflect these pre-existing risks, a treatment interruption, or both. Their occurrence after the restriction would not, by itself, establish that the restriction caused them.

Claims incompletely capture pain, functioning, and care obtained outside insurance coverage. Clinical records and patient accounts could help establish whether changes in dispensing were accompanied by improvements in care.

Despite these challenges, evaluation could provide actionable evidence. Transitions to appropriate care, accompanied by fewer adverse events, would strengthen the clinical rationale for blocking. Appropriate care might include continued opioid treatment when clinically indicated, other pain management, or treatment for opioid use disorder; success would not be defined by opioid discontinuation alone. Continued dangerous dispensing elsewhere would suggest a need for better coordination across pharmacies and clinicians. Prolonged treatment gaps would identify patients for whom additional transition support warrants assessment. Each finding would contribute to a more effective response to unsafe prescribing.

We know what the agreement requires, and we have not established that CVS cuts patients off without follow-up. The purpose of evaluation is to examine that transition, not presume its failure. The absence of an explicit patient-outcome reporting requirement identifies a limitation in what the mandated reports can establish, rather than evidence that follow-up does not occur.

The settlement provides a framework for restricting unsafe dispensing. Patient follow-up could strengthen that framework by identifying whether the intended protection extends beyond the pharmacy counter. Patients should remain part of the assessment wherever they subsequently receive care.

Stopping harmful prescribing and securing safer treatment are connected patient-safety objectives. An evidence-informed response should assess both.